Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMP7XG)

Drug Name

MAXY-4 Drug Info

Synonyms

CTLA4-Ig proteins (rheumatoid arthritis), Maxygen

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-lymphocyte activation antigen CD86 (FUN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abatacept	DMSA8RU	Alopecia areata	ED70.2	Approved	[3]
Tolerimab	DMZKIE0	Transplant rejection	NE84	Terminated	[4]
------------------------------------------------------------------------------------

Drug(s) Targeting Activation B7-1 antigen (CD80)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abatacept	DMSA8RU	Alopecia areata	ED70.2	Approved	[3]
RhuDex	DMGM1IR	Rheumatoid arthritis	FA20	Phase 2a	[5]
HS-110	DML4RCG	Non-small-cell lung cancer	2C25.Y	Phase 2	[6]
Galiximab	DMTXCUS	Lymphoma	2A80-2A86	Phase 2	[7]
CAR-T cells targeting CD80/86	DM6Z7AD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
Tolerimab	DMZKIE0	Transplant rejection	NE84	Terminated	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Activation B7-1 antigen (CD80)	TTFZDNP	CD80_HUMAN	Inhibitor	[2]
T-lymphocyte activation antigen CD86 (FUN1)	TTHGXBU	CD86_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02052375) A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With RheumatoidArthritis on Methotrexate. U.S. National Institutes of Health.
2	Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3.
3	Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8.
4	US patent application no. 2004,0171,123, Albumin fusion proteins.
5	A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
6	Clinical pipeline report, company report or official report of Heat Biologics.
7	Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8.
8	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers